摘要
目的 观察健择 (GEM )、顺铂 (DDP)组成的GP方案和诺维本 (NVB)、异环磷酰胺 (IFO)、DDP组成的NIP方案治疗非小细胞肺癌的疗效和安全性。方法 80例Ⅲ～Ⅳ期NSCLC患者分为两组 ,每组 40例。一组予以GP方案 :GEM 10 0 0mg/m2 ,第 1、8或 15天 ;DDP 70～ 80mg/m2 ,第 1天。另一组予以NIP方案 :NVB 2 5mg/m2 ,第 1、8天 ;IFO 1.2g/m2 ,第 1～ 4天连续给药 ;DDP 70～ 80mg/m2 ,第 1天。结果 GP组和NIP组有效率分别为 40 .0 %和 5 2 .5 % ,无统计学差异。GP组和NIP组中位生存期分别为 13 .68个月和15 .3 4个月 ,1年生存率分别为 5 4.2 9%和 5 9.46% (P >0 .0 5 )。Ⅲ～Ⅳ度白细胞减少发生率GP组和NIP组分别为 2 7.5 %和 5 5 .0 % (P <0 .0 5 )。非血液毒性反应GP组大多低于NIP组 (P <0 .0 5 )。结论 三药联合化疗方案虽然在疗效上略高于两药联合化疗方案 ,但无显著性差异 ,却增加了毒副反应。两药联合化疗方案GP是治疗晚期NSCLC患者的有效方案。而对于年纪较轻。
Objective To compare the effect and toxicity between gemcitabine and cisplatin (GP) with vinorelbine, ifosfamide and cisplatin (NIP) combined chemotherapy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods Eighty patients received either gemcitabine 1 000 mg/m 2 on days 1, 8, or 15 plus cisplatin 70--80 mg/m 2 on day 1, or vinorelbine 25 mg/m 2 on days 1, 8, ifosfamide 1.2 g/m 2 on days 1--4 plus cisplatin 70--80 mg/m 2 on day 1, every 28 days as a cycle. Results The objective response rate was 40.0% in GP goup, compared with 52.5% in NIP group (P>0.05). Median survival time of GP and NIP groups was 13.68 and 15.34 months respectively, and 1-year survival rates were 54.29% and 59.46% respectively (P>0.05). Leukopenia at grade Ⅲ+Ⅳ was significantly lower in GP arm (27.5%) than that in NIP arm (55.0%) (P<0.05). Non-hematological toxicities were less frequent in GP group than those in NIP group (P<0.05). Conclusion Although the response rate tends to be higher in three-drug than in two-drug combined chemotherapy, but no significant difference is observed. Three-drug combinations often result in more toxicities. Two-drug combination GP may be the standard protocol for chemotherapy of advanced NSCLC. Three-drug combination NIP should be given to young patients with good performance status.
出处
《中国肺癌杂志》
CAS
2004年第5期449-451,共3页
Chinese Journal of Lung Cancer
关键词
非小细胞肺癌
化疗
健择
诺维本
异环磷酰胺
顺铂
Non-small cell lung cancer Chemotherapy Gemcitabine Vinorelbine Ifosfamide Cisplatin
